The Asociación Española Contra el Cáncer (Spanish Association Against Cancer) in Castilla y León, with the nine provincial offices as organizers (Zamora, Ávila, Segovia, Soria, Salamanca, Burgos, León, Palencia y Valladolid) has presented the concert to be performed on 18 March on the occasion of the 50th anniversary of the Association’s cancer research. The event is sponsored by Unicaja Banco and is has the support of Junta de Castilla y León.
The association commemorates its commitment to science for half a century to increase cancer survival and improve the quality of life of patients.
The event, which will begin at 19:30, will take place at Auditorio Miguel Delibes in Valladolid (Av. del Real Valladolid, 2), with the Castilla y León Symphony Orchestra conducted by Julio García Vico. The orchestra will play works by Falla, Weber and Stravinsky. The young clarinetist Claudia Aliaj will also perform.
The recital will be attended by the president of Asociación Española Contra el Cáncer, Ramón Reyes; the president of the association in Valladolid, Artemio Domínguez, and the rest of the representatives of the provincial branches of the association in the region. It will be the second in a series of concerts that will be held in other cities of Spain, ending in Madrid with the National Orchestra and Choir of Spain on 15 September 2022.
50 years of research to change the history of cancer
Since 1971, when the association created the AECC Scientific Foundation to support cancer research, at a time when society did not give science the importance it currently receives, the organization began to make history. Since then, based on this support for research, Asociación Española Contra el Cáncer has tried to respond to the great challenges of cancer by promoting research talent. Thanks to the support that the Spanish society has been offering, the association has allocated funds to achieve advances that allow for early detection of the disease, prevention and the development of increasingly effective and less invasive therapies against different types of tumors.
In addition, the organization works to ensure that cancer is the same for everyone. In this sense, its objective is that all patients have the right to research on their type of cancer and to reach a 70% survival rate by the year 2030. Achieving this goal involves increasing research into those tumors with stagnant survival rates (pancreas, esophagus, etc.), so as to narrow the differences with some cancers whose survival rates are above 80%.
